Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 3, 2015, Pages 797-808

  Rangaraju, Srikant ^a   Gearing, Marla ^a   Jin, Lee Way ^b   Levey, Allan ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Kv1.3; microglia; neuroinflammation; potassium channel

Indexed keywords

AMYLOID BETA PROTEIN; POTASSIUM CHANNEL KV1.3; AIF1 PROTEIN, HUMAN; DNA BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; TUBB3 PROTEIN, HUMAN; TUBULIN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN TISSUE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MICROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WESTERN BLOTTING; BRAIN; FEMALE; MALE; METABOLISM; PATHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; DNA-BINDING PROTEINS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; KV1.3 POTASSIUM CHANNEL; MALE; MICROGLIA; TUBULIN;

EID: 84922598763     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141704     Document Type: Article

References (47)

1. Lehnardt S (2010) Innate immunity and neuroinflammation in the CNS: The role of microglia in Toll-like receptor-mediated neuronal injury. Glia 58, 253-263.
2. Varnum MM, Ikezu T (2012) The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) 60, 251-266.
3. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28, 8354-8360.
4. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368, 107-116.
5. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. Nat Neurosci 16, 848-850.
6. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368, 117-127.
7. Kotecha SA, Schlichter LC (1999) A Kv1. 5 to Kv1. 3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci 19, 10680-10693.
8. Schilling T, Eder C (2011) Amyloid-beta-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia. J Cell Physiol 226, 3295-3302.
9. Rangaraju S, Chi V, Pennington MW, Chandy KG (2009) Kv1. 3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin Ther Targets 13, 909-924.
10. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671-675.
11. Guntern R, Bouras C, Hof PR, Vallet PG (1992) An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease. Experientia 48, 8-10.
12. Hales CM, Rees H, Seyfried NT, Dammer EB, Duong DM, Gearing M, Montine TJ, Troncoso JC, Thambisetty M, Levey AI, Lah JJ, Wingo TS (2013) Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes. J Neuropathol Exp Neurol 72, 1009-1015.
13. Wulff H, Knaus HG, Pennington M, Chandy KG (2004) K+ channel expression during B cell differentiation: Implications for immunomodulation and autoimmunity. J Immunol 173, 776-786.
14. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, StreitW, Strohmeyer R, Tooyoma I, VanMuiswinkel FL,Veerhuis R,Walker D,Webster S,Wegrzyniak B,Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
15. Jiang T, Yu JT, Zhu XC, Tan L (2013) TREM2 in Alzheimer's disease. Mol Neurobiol 48, 180-185.
16. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643.
17. Saijo K, Glass CK (2011) Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 11, 775-787.
18. Colton CA (2009) Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 4, 399-418.
19. Grathwohl SA, Kalin RE, Bolmont T, Prokop S,Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M (2009) Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 12, 1361-1363.
20. Weitz TM, Town T (2012) Microglia in Alzheimer's disease: It's all about context. Int J Alzheimers Dis 2012, 314185.
21. Cahalan MD, Chandy KG (2009) The functional network of ion channels in T lymphocytes. Immunol Rev 231, 59-87.
22. Fischer HG, Eder C, Hadding U, Heinemann U (1995) Cytokine-dependent K+ channel profile of microglia at immunologically defined functional states. Neuroscience 64, 183-191.
23. Kaushal V, Koeberle PD, Wang Y, Schlichter LC (2007) The Ca2+-activated K+ channel KCNN4/KCa3. 1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 27, 234-244.
24. Mullen KM, Rozycka M, Rus H, Hu L, Cudrici C, Zafranskaia E, Pennington MW, Johns DC, Judge SI, Calabresi PA (2006) Potassium channels Kv1. 3 and Kv1. 5 are expressed on blood-derived dendritic cells in the central nervous system. Ann Neurol 60, 118-127.
25. Schilling T, Eder C (2009) Importance of the non-selective cation channel TRPV1 for microglial reactive oxygen species generation. J Neuroimmunol 216, 118-121.
26. Beeton C,Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG (2006) Kv1. 3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A 103, 17414-17419.
27. Khanna R, Roy L, Zhu X, Schlichter LC (2001) K+ channels and the microglial respiratory burst. AmJ Physiol Cell Physiol 280, C796-806.
28. Fordyce CB, Jagasia R, Zhu X, Schlichter LC (2005) Microglia Kv1. 3 channels contribute to their ability to kill neurons. J Neurosci 25, 7139-7149.
29. Skaper SD (2011) Ion channels on microglia: Therapeutic targets for neuroprotection. CNS Neurol Disord Drug Targets 10, 44-56.
30. Maezawa I, Zimin PI,Wulff H, Jin LW(2011) Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 286, 3693-3706.
31. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68, 930-941.
32. Schilling T, Quandt FN, Cherny VV, ZhouW, Heinemann U, Decoursey TE, Eder C (2000) Upregulation of Kv1. 3 K(+) channels in microglia deactivated by TGF-beta. Am J Physiol Cell Physiol 279, C1123-1134.
33. Maezawa I, Jenkins PD, Sexton J, Wulff H, Jin LW (2012) The role of potassium channel Kv1. 3 inAinduced microglia activation. Alzheimers Dement 8 (Suppl), P301.
34. Lioudyno MI, Broccio M, Sokolov Y, Rasool S,Wu J, Alkire MT, Liu V, Kozak JA, Dennison PR, Glabe CG, Losche M, Hall JE (2012) Effect of synthetic abeta peptide oligomers and fluorinated solvents on Kv1. 3 channel properties and membrane conductance. PLoS One 7, e35090.
35. Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, Kuperschmidt S, Kurachi Y, Lazdunski M, Lesage F, Lester HA, McKinnon D, Nichols CG, O'Kelly I, Robbins J, Robertson GA, Rudy B, Sanguinetti M, Seino S, Stuehmer W, Tamkun MM, Vandenberg CA, Wei A, Wulff H, Wymore RS (2003) International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: Potassium channels. Pharmacol Rev 55, 583-586.
36. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, Chandy KG (1994) Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1. 1, 1. 2, 1. 3, 1. 5, and 3. 1, stably expressed in mammalian cell lines. Mol Pharmacol 45, 1227-1234.
37. Veh RW, Lichtinghagen R, Sewing S, Wunder F, Grumbach IM, PongsO(1995) Immunohistochemical localization of five members of the Kv1 channel subunits: Contrasting subcellular locations and neuron-specific co-localizations in rat brain. Eur J Neurosci 7, 2189-2205.
38. Fadool DA, Tucker K, Perkins R, Fasciani G, Thompson RN, Parsons AD, Overton JM, Koni PA, Flavell RA, Kaczmarek LK (2004) Kv1. 3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron 41, 389-404.
39. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PA (2005) The voltage-gated potassium channel Kv1. 3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 102, 11094-11099.
40. Cornblath DR, Bienen EJ, Blight AR (2012) The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clin Ther 34, 1056-1069.
41. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR (2010)Aphase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68, 494-502.
42. Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG (2009) Engineering a stable and selective peptide blocker of the Kv1. 3 channel in T lymphocytes. Mol Pharmacol 75, 762-773.
43. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flugel A, Pennington MW, Parker I, Chandy KG, Cahalan MD (2008) Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1. 3 channel block. Immunity 29, 602-614.
44. Kineta, http://www. kinetabio. com/pipeline. html, Accessed 01/11/2014.
45. Menteyne A, Levavasseur F, Audinat E, Avignone E (2009) Predominant functional expression of Kv1. 3 by activated microglia of the hippocampus after Status epilepticus. PLoS One 4, e6770.
46. Liu J, Xu P, Collins C, Liu H, Zhang J, Keblesh JP, Xiong H (2013) HIV-1 Tat protein increases microglial outward K(+) current and resultant neurotoxic activity. PLoS One 8, e64904.
47. Peng Y, Lu K, Li Z, Zhao Y,Wang Y, Hu B, Xu P, Shi X, Zhou B, Pennington M, Chandy KG, Tang Y (2014) Blockade of Kv1. 3 channels ameliorates radiation-induced brain injury. Neuro Oncol 16, 528-539.